Oruka Therapeutics, Inc., a biotechnology company focused on treatments for chronic skin diseases, has announced the promotion of Laura Sandler to Chief Operating Officer. Sandler, who joined Oruka in 2024 as SVP of Operations, has extensive experience in biopharmaceutical leadership and has been instrumental in advancing the company's clinical programs. Prior to Oruka, she held senior roles at CRISPR Therapeutics, MedImmune, Quintiles, Novartis, and bluebird bio.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487023-en) on July 01, 2025, and is solely responsible for the information contained therein.